Prostate Cancer Prostatic Dis. 2003;6(4):301-4.

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.

Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI.

Source

Prostate Oncology Specialist, Marina del Rey, California 90292, USA. Brad@prost8cancer.com

Abstract

This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.

PMID:: 14663471; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Prostate Cancer - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. [Int J Radiat Oncol Biol Phys. ...]
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK, Levy LB, Cheung R, Kuban D. Int J Radiat Oncol Biol Phys. 2005 Oct 1; 63(2):456-62.
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. [J Clin Oncol. 2006]
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. J Clin Oncol. 2006 Jun 20; 24(18):2723-8.
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. [J Urol. 2006]
A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
North SA, Graham K, Bodnar D, Venner P. J Urol. 2006 Jul; 176(1):91-5.
Review Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time. [J Insur Med. 2003]
Review Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time.
Ashley T. J Insur Med. 2003; 35(3-4):161-4.
Review [PSA and follow-up after treatment of prostate cancer]. [Prog Urol. 2008]
Review [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P. Prog Urol. 2008 Mar; 18(3):137-44. Epub 2008 Apr 18.

See reviews... See all...

Cited by 3 PubMed Central articles

Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin. [BMC Complement Altern Med. 2011]
Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.
Ramachandran C, Wilk BJ, Hotchkiss A, Chau H, Eliaz I, Melnick SJ. BMC Complement Altern Med. 2011 Aug 4; 11:59. Epub 2011 Aug 4.
Microbial utilization and selectivity of pectin fractions with various structures. [Appl Environ Microbiol. 2011]
Microbial utilization and selectivity of pectin fractions with various structures.
Onumpai C, Kolida S, Bonnin E, Rastall RA. Appl Environ Microbiol. 2011 Aug 15; 77(16):5747-54. Epub 2011 Jul 1.
Review Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. [Carbohydr Res. 2009]
Review Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.
Glinsky VV, Raz A. Carbohydr Res. 2009 Sep 28; 344(14):1788-91. Epub 2008 Sep 26.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling ti...
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Prostate Cancer Prostatic Dis. 2003 ;6(4):301-4.

PubMed
The interaction between St John's wort and an oral contraceptive.
The interaction between St John's wort and an oral contraceptive.
Clin Pharmacol Ther. 2003 Dec ;74(6):525-35.

PubMed
Long-term hearing preservation after middle fossa removal of vestibular schwanno...
Long-term hearing preservation after middle fossa removal of vestibular schwannoma.
Otolaryngol Head Neck Surg. 2003 Dec ;129(6):660-5.

PubMed
Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell an...
Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas.
Appl Immunohistochem Mol Morphol. 2003 Dec ;11(4):330-3.

PubMed
Pixel-by-pixel spatiotemporal progression of focal ischemia derived using quanti...
Pixel-by-pixel spatiotemporal progression of focal ischemia derived using quantitative perfusion and diffusion imaging.
J Cereb Blood Flow Metab. 2003 Dec ;23(12):1479-88.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: